BOOSTRIX-POLIO DIN 02312557
Status: Marketed
Holder: GLAXOSMITHKLINE INC
Health Canada record
| Active ingredient(s) | DIPHTHERIA TOXOID ADSORBED 2.5 LF; TETANUS TOXOID ADSORBED 5.0 LF; PERTUSSIS TOXOID ADSORBED 8 MCG; FILAMENTOUS HAEMAGGLUTININ ADSORBED 8 MCG; PERTACTIN ADSORBED 2.5 MCG; INACTIVATED POLIOVIRUS TYPE I 40 D; INACTIVATED POLIOVIRUS TYPE II 8 D; INACTIVATED POLIOVIRUS TYPE III 32 D |
|---|
| Dosage form | Suspension |
|---|
| Route | Intramuscular |
|---|
| Schedule | SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | J07CA02 DIPHTHERIA-PERTUSSIS-POLIOMYELITIS-TETANUS |
|---|
| Original market date | 22-Oct-2010 |
|---|
| Current status date | 22-Oct-2010 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
GlaxoSmithKline Inc. — licence 100630, currently licensed, last inspection rating C (2025-09-15).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DIPHTHERIA TOXOID ADSORBED
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02528401 | TD ADSORBED | SANOFI VACCINES CANADA LTD. | Suspension | DIPHTHERIA TOXOID ADSORBED 2 LF; TETANUS TOXOID ADSORBED 5 LF | Marketed |
| 00514462 | TD ADSORBED | SANOFI VACCINES CANADA LTD. | Suspension | DIPHTHERIA TOXOID ADSORBED 2 LF; TETANUS TOXOID ADSORBED 5 LF | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 9612 | 2008-06-12 | New Drug Submission (NDS) | |
Request a quote for BOOSTRIX-POLIO
How to read a Canadian DIN record